JPMorgan Chase & Co. Cuts Dyne Therapeutics (NASDAQ:DYN) Price Target to $16.00

Dyne Therapeutics (NASDAQ:DYN) had its price target lowered by JPMorgan Chase & Co. from $17.00 to $16.00 in a research note published on Tuesday,Benzinga reports. The firm currently has a neutral rating on the stock.

DYN has been the subject of a number of other reports. Morgan Stanley lifted their price target on shares of Dyne Therapeutics from $46.00 to $50.00 and gave the company an “overweight” rating in a research report on Monday, December 8th. Sanford C. Bernstein set a $23.00 price objective on shares of Dyne Therapeutics in a research report on Tuesday, December 9th. Evercore ISI dropped their target price on shares of Dyne Therapeutics from $38.00 to $36.00 and set an “outperform” rating for the company in a report on Monday, December 15th. TD Cowen restated a “buy” rating on shares of Dyne Therapeutics in a research note on Monday, December 8th. Finally, Robert W. Baird set a $30.00 price target on Dyne Therapeutics in a research report on Monday, December 8th. Three research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Dyne Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $38.41.

Dyne Therapeutics Price Performance

NASDAQ:DYN opened at $18.08 on Tuesday. Dyne Therapeutics has a 52 week low of $6.36 and a 52 week high of $25.00. The stock’s fifty day moving average is $19.39 and its two-hundred day moving average is $15.65. The company has a market capitalization of $2.58 billion, a P/E ratio of -4.94 and a beta of 1.32. The company has a quick ratio of 13.47, a current ratio of 13.47 and a debt-to-equity ratio of 0.14.

Dyne Therapeutics (NASDAQ:DYN) last issued its quarterly earnings data on Wednesday, November 5th. The company reported ($0.76) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.81) by $0.05. Equities analysts expect that Dyne Therapeutics will post -3.44 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Darwin Wealth Management LLC increased its holdings in Dyne Therapeutics by 0.5% during the 3rd quarter. Darwin Wealth Management LLC now owns 173,517 shares of the company’s stock worth $2,195,000 after purchasing an additional 861 shares during the period. Ameritas Investment Partners Inc. increased its stake in shares of Dyne Therapeutics by 11.1% during the second quarter. Ameritas Investment Partners Inc. now owns 9,582 shares of the company’s stock worth $91,000 after buying an additional 955 shares during the period. Creative Planning raised its holdings in Dyne Therapeutics by 6.8% in the third quarter. Creative Planning now owns 15,527 shares of the company’s stock valued at $196,000 after acquiring an additional 986 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in Dyne Therapeutics by 25.3% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,500 shares of the company’s stock worth $70,000 after acquiring an additional 1,109 shares during the last quarter. Finally, Caxton Associates LLP lifted its stake in Dyne Therapeutics by 10.9% in the second quarter. Caxton Associates LLP now owns 16,599 shares of the company’s stock worth $158,000 after acquiring an additional 1,627 shares during the last quarter. 96.68% of the stock is currently owned by hedge funds and other institutional investors.

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.